Mallinckrodt to create 45 new jobs with €45m investment

Company establishing a new manufacturing facility in Dublin

Minister for Health Leo Varadkar pictured with Mallinckrodt chief executive Mark Trudeau at an earlier announcement by the company

Minister for Health Leo Varadkar pictured with Mallinckrodt chief executive Mark Trudeau at an earlier announcement by the company

 

Dublin-domiciled specialty pharmaceuticals company Mallinckrodt is to create 45 highly-skilled jobs as part of a €45 million investment.

The company is to establish a new manufacturing facility at the College Business and Technology Park in Blanchardstown, Dublin 15.

The development will provide 300 jobs during the two-year construction phase and 45 skilled positions once the facility is completed.

The new development is to include a two-storey manufacturing building, a three-storey administration building and additional areas for future investment on a c.4.85 hectare site.

Mallinckrodt, which has its headquarters in Mulhuddart, Dublin 15 but operates from its location in Missouri in the US, is a global specialty biopharmaceutical and medical imaging business that develops, manufactures, markets and distributes specialty pharmaceutical products and medical imaging agents. Mallinckrodt was spun-off by Covidien in 2013.

The company, which currently employs more than 120 people at its existing manufacturing site and offices in Dublin, said it has invested more than €165 million in Ireland over the past 22 years.

“We are proud to have had a significant presence in Ireland for over two decades, and today marks an important step for the company. Our Irish workforce has served as a tremendous asset to our global operations to date. We are particularly pleased to be making this sizeable capital investment today, continuing our long-standing operations in Ireland,” said Mallinckrodt chief executive and president Mark Trudeau.